Greg Verdine’s LifeMine eyes the clinic next year with T-cell immunosuppressive and antifungal: #JPM24

Kyle LaHucik

Senior Reporter

SAN FRANCISCO — LifeMine Therapeutics, a biotech informed by the long history of fungi, expects to enter the clinic early next year with a T-cell immunosuppressive and with an antifungal about six months later, CEO Greg Verdine told Endpoints News.

“I’m saying it for the first time that these are the two areas right now that we’re focusing in,” Verdine said in an interview on the sidelines of the annual JP Morgan Healthcare Conference in the Bay Area. The biotech is also working on oncology programs and elsewhere, he noted.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Greg Verdine’s LifeMine eyes the clinic next year with T-cell immunosuppressive and antifungal: #JPM24

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Updated: US intelligence officials told Congress that WuXi transferred IP to Chinese authorities — report

FDA gives the green light to AstraZeneca's rare blood disorder drug Voydeya, following approval in Japan

Bristol Myers' Zeposia expansion plans hit by Phase 3 setback in Crohn's disease

Walgreens reports a $5.8B charge due to clinic operator VillageMD

Gilead pays $43M to license Xilio’s IL-12 program that could turn ‘cold’ tumors ‘hot’

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Greg Ver­dine’s LifeM­ine eyes the clin­ic next year with T-cell im­muno­sup­pres­sive and an­ti­fun­gal: #JPM24

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Up­dat­ed: US in­tel­li­gence of­fi­cials told Con­gress that WuXi trans­ferred IP to Chi­nese au­thor­i­ties — re­port

FDA gives the green light to As­traZeneca's rare blood dis­or­der drug Voydeya, fol­low­ing ap­proval in Japan

Bris­tol My­er­s' Zeposia ex­pan­sion plans hit by Phase 3 set­back in Crohn's dis­ease

Wal­greens re­ports a $5.8B charge due to clin­ic op­er­a­tor Vil­lageMD

Gilead pays $43M to li­cense Xilio’s IL-12 pro­gram that could turn ‘cold’ tu­mors ‘hot’

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Greg Verdine’s LifeMine eyes the clinic next year with T-cell immunosuppressive and antifungal: #JPM24

Updated: US intelligence officials told Congress that WuXi transferred IP to Chinese authorities — report

FDA gives the green light to AstraZeneca's rare blood disorder drug Voydeya, following approval in Japan

Bristol Myers' Zeposia expansion plans hit by Phase 3 setback in Crohn's disease

Walgreens reports a $5.8B charge due to clinic operator VillageMD

Gilead pays $43M to license Xilio’s IL-12 program that could turn ‘cold’ tumors ‘hot’

Medical Affairs: The Critical Link Between Science, Physicians and Patients